Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rel-Menthone SCHEMBL111746 | 0.90 | LMNA (0.32) | LMNACYP2D6 | |
| Menthone SCHEMBL3652908 | 0.90 | LMNA (0.32) | LMNACYP2D6 | |
| Menthone SCHEMBL901274 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Menthone SCHEMBL4395963 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Rel-Isomenthone SCHEMBL650578 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Menthone SCHEMBL21709 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Menthone SCHEMBL13255148 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Rel-Menthone SCHEMBL1868327 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Rel-Menthone SCHEMBL21711 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 | |
| Menthone SCHEMBL12326763 | 0.84 | TLR4 (0.39) | TLR4NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117355218-A | Flavor beads and methods of making and using the same | 威·曼父子有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-101242807-B | Mouth-moistening compositions, delivery systems comprising the same, and methods of making the same | KRAFT FOODS GLOBAL BRANDS LLC | 2014-12-10 | — | — | CN | disclosed |
| US-8735609-B2 | Bryostatin analogues, synthetic methods and uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8497385-B2 | Bryostatin analogues, synthetic methods and uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130123518-A1 | Bryostatin Analogues, Synthetic Methods and Uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-05-16 | — | — | US | disclosed |
| CN-101522221-B | Process for manufacturing a delivery system for an active component being part of an edible composition | KRAFT FOODS GLOBAL BRANDS LLC | 2013-04-24 | — | — | CN | disclosed |
| CN-101282707-B | Cooling compositions comprising menthyl esters | KRAFT FOODS GLOBAL BRANDS LLC | 2013-03-27 | — | — | CN | disclosed |
| US-8344025-B2 | Oxalic acid derivatives and use thereof as physiological cooling active ingredients | SYMRISE AG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8242289-B2 | Alkyl-substituted tetrahydropyrans as flavoring substances | SYMRISE AG (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20100280262-A1 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| CN-101242807-A | Mouth-moistening compositions, delivery systems comprising the same, and methods of making the same | CADBURY ADAMS USA LLC (US) | 2008-08-13 | — | — | CN | disclosed |
| US-20070270485-A1 | Byrostatin analogues, synthetic methods and uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2007-11-22 | — | — | US | disclosed |
| US-7256286-B2 | Bryostatin analogues, synthetic methods and uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1233956-A4 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | UNIV LELAND STANFORD JUNIOR (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20030220334-A1 | Byrostatin analogues, synthetic methods and uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-11-27 | — | — | US | disclosed |
| US-6624189-B2 | Anticancer agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-09-23 | — | — | US | disclosed |
| WO-2003070719-A1 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020137789-A1 | Byrostatin analogues, synthetic methods and uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | disclosed |
| EP-1233956-A1 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040214-A1 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220334-A1 | Byrostatin analogues, synthetic methods and uses | BID, HASPIN, HPGDS | LMNA 1818/4885CYP2D6 3906/4885TLR4 4438/4885 |
| US-20070270485-A1 | Byrostatin analogues, synthetic methods and uses | BID, HASPIN, HPGDS | LMNA 1818/4885CYP2D6 3906/4885TLR4 4438/4885 |
| US-20020137789-A1 | Byrostatin analogues, synthetic methods and uses | BID, IGF2BP1, IGFBP4 | LMNA 1557/4885CYP2D6 4281/4885TLR4 4487/4885 |
| US-20100280262-A1 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES | MCL1, PBK, BID | LMNA 2826/4885CYP2D6 4342/4885TLR4 3966/4885 |
| US-20130123518-A1 | Bryostatin Analogues, Synthetic Methods and Uses | MCL1, PBK, BID | LMNA 2826/4885CYP2D6 4342/4885TLR4 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.